
Opinion|Videos|March 14, 2025
JAK V617F Monitoring and Risk Assessment Tools: Optimizing Treatment Decisions in MPN
Author(s)Daniel Landau, MD
An expert discusses how advances in JAK V617F monitoring have improved the assessment of disease status and guided treatment decisions and how risk assessment tools have transformed the ability to optimize treatment selection in patients with myeloproliferative neoplasms (MPNs).
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Please discuss how advances in JAK V617F monitoring have empowered you to better assess disease status and guide treatment decisions.
- Please share how risk assessment tools have transformed your ability to optimize treatment selection in patients with MPNs.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Speed Is the Story: How Sequencing the Human Genome Transformed Cancer Care
2
Zoldonrasib Combos, Including With Daraxonrasib, Yield High Response Rates in PDAC
3
Lung Cancer News Roundup: June 2026
4
Examining the Strongest Options for Heavily Pretreated Myeloma After Bispecific Therapy
5









































